La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kindly MD a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kindly MD..

Kindly MD (NASDAQ:KDLY) Azioni, Catena delle Opzioni

Kindly MD

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Kindly MD Inc

Guidance The company today issued its fiscal year 2026 (FY26) revenue growth and EPS guidance.
The company is guiding to FY26 organic revenue growth of approximately 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY26 revenue growth on a reported basis would be in the range of 4.8% to 5.1%.
Excluding the potential impacts from increased tariffs, Medtronic expects FY26 diluted non-GAAP EPS growth to be approximately 4%. This includes an expectation for non-GAAP operating profit to grow faster than organic revenue, partially offset by increased interest and tax expense. Including a potential impact from tariffs as detailed in the company's earnings presentation, Medtronic is guiding FY26 diluted non-GAAP EPS in the range of $5.50 to $5.60. The lower end of the EPS range assumes that the bilateral US/China tariffs resume at the higher rates following the 90 day pause, while the higher end of the EPS range assumes that the bilateral US/China tariffs currently in effect during the pause remain in place through fiscal year 2026.
"Our fiscal 2026 guidance reflects increasing revenue growth contribution from our key growth drivers, and increased investment to support their growth, leading to leveraged operating profit growth pre-tariffs. In addition, the team has rallied to identify opportunities to offset a large portion of tariffs, and we have high confidence in our ability to execute additional mitigation efforts," said Thierry Piéton, Medtronic chief financial officer, who joined the company on March 3, 2025. "This is an exciting time to join Medtronic. I am energized by the opportunities for durable growth and value creation ahead of us."

News

Guidance

Medtronic Sees FY2026 Adj EPS $5.50-$5.60 Vs $5.83 Est., Sees 5% Organic Revenue Growth

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) with a Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

DTIL

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

URGN

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Dividend Increase The company today announced that effective May 20, 2025, the Medtronic board of directors approved an increase in Medtronic's cash dividend for the first quarter of fiscal year 2026, raising the quarterly amount to $0.71 per ordinary share. This would translate into an annual amount of $2.84 per ordinary share. Today's announcement marks the 48th consecutive year of an increase in the dividend payment. The dividend is payable on July 11, 2025, to shareholders of record at the close of business on June 27, 2025.

Dividends

Medtronic Boosts Quarterly Dividend By 1.4% To $0.71, Payable July 11

Needham analyst Scott Berg reiterates Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy and maintains $300 price target.

WDAY

Needham Reiterates Buy on Workday, Maintains $300 Price Target

Outlook
Considering ongoing macroeconomic uncertainty and dynamic consumer spending patterns brought on by the unpredictable global trade environment, Canada Goose will not be providing a financial outlook for fiscal 2026.
Management remains confident in the strength of the brand, the Company's solid financial position, and its ability to adapt to changing conditions.

GOOS

Canada Goose Does Not Provide FY26 Financial Outlook Due To Ongoing Macroeconomic Uncertainty

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.58 by 2.53 percent. This is a 10.96 percent increase over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $8.93 billion which beat the analyst consensus estimate of $8.82 billion by 1.17 percent. This is a 3.94 percent increase over sales of $8.59 billion the same period last year.

Earnings

Earnings Beats

Medtronic Q4 Adj. EPS $1.62 Beats $1.58 Estimate, Sales $8.93B Beat $8.82B Estimate

LXP Industrial Trust Announced That It Executed A Lease For Its Approximately 1.1 Million Square Foot Industrial Facility In The Greenville/Spartanburg, South Carolina Market

Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services,&nbsp;today announced it has been awarded a seat on a multi-year, $4.0 Billion, Emergency Detention and Related Services Strategic Sourcing Vehicle ("SSV").
The SSV establishes the contracting vehicle necessary to support the Department of Homeland Security ("DHS") and U.S. Immigration and Customs Enforcement ("ICE") response to certain Executive Orders issued on January 20, 2025. The SSV is intended to support DHS and ICE's initiatives focused on expanding emergency detention capabilities and related facility services. The SSV has a total contract value up to $4.0 billion with a period of performance through May 16, 2027.

Target Hospitality Awarded Seat On Multi-Year, $4.0B, Emergency Detention And Related Services Strategic Sourcing Vehicle

Medtronic Announced Its Intent To Separate Its Diabetes Business Into A New Standalone Company

Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.16 by 43.75 percent. This is a 64.29 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $267.92 million which beat the analyst consensus estimate of $262.86 million by 1.92 percent. This is a 0.87 percent increase over sales of $265.61 million the same period last year.

Canada Goose Hldgs Q4 Adj. EPS $0.23 Beats $0.16 Estimate, Sales $267.92M Beat $262.86M Estimate

Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Hold to Hold.

STAA

Needham Reiterates Hold on Staar Surgicalto Hold

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Hold.

GILD

Needham Reiterates Hold on Gilead Sciencesto Hold

The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
What Happened: The FDA will now require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under age 65, effectively restricting their availability to older adults and those at risk of severe illness, according to FDA Commissioner Marty Makary and top U.S. vaccines regulator Vinay Prasad in the New England Journal of Medicine, reported Reuters.
&#8220;At-risk Americans can be reassured that they will be covered by such approvals. At the same time, we want more evidence at the U.S. Food and Drug Administration,&#8221; Prasad told FDA scientists during a live-streamed presentation on Tuesday. &#8220;We want to know more about what these products are doing, especially as we enter the seventh, eighth and ninth dose.&#8221;
See Also: <a href="https://www.benzinga.com/markets/25/05/45537306/google-unveils-total-reimagining-of-search-with-chatbot-style-feature-to-compete-with-openai">Google Unveils &#8216;Total Reimagining Of Search&#8217; With Chatbot-Style Feature To Compete With OpenAI</a> Why It Matters: This policy shift represents a significant departure from previous U.S. vaccination strategy, with Makary and Prasad noting that America has been more aggressive than other high-income nations in recommending yearly shots for healthy adults.
The decision comes amid shifting political priorities at the FDA under Health Secretary Robert F. Kennedy Jr., who has been remaking the U.S. health system to align with President Donald Trump&#8216;s goal of dramatically <a href="https://www.benzinga.com/government/regulations/25/05/45488265/novavax-wins-limited-fda-nod-for-covid-shot-cleared-only-for-seniors-high-risk-groups-amid-safety-scrutiny">shrinking the federal government</a>. 
This follows a pattern of increased scrutiny of vaccines, as evidenced by the FDA&#8217;s recent limited approval of Novavax Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 vaccine only for <a href="https://www.benzinga.com/government/regulations/25/05/45488265/novavax-wins-limited-fda-nod-for-covid-shot-cleared-only-for-seniors-high-risk-groups-amid-safety-scrutiny">people 65 and older and those 12</a> and up with underlying health conditions.
Despite the policy change, investors appeared reassured that vaccine policies for older and high-risk Americans remain unchanged. Shares of COVID-19 vaccine makers rose following the announcement, with Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) up 6.06%, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) rising 2.22%, BioNTech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) U.S. ADRs up 4.1%, and Novavax gaining 1.5%.
Image Via Shutterstock 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45537159/gary-black-compares-ubers-shift-to-driverless-cars-with-netflixs-2007-move-from-dvds-to-streaming-says-tesla-faithful-are-missing-the-bigger-picture">Gary Black Compares Uber&#8217;s Shift To Driverless Cars With Netflix&#8217;s 2007 Move From DVDs To Streaming, Says Tesla &#8216;Faithful&#8217; Are Missing The Bigger Picture</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Biotech

Regulations

Health Care

BNTX

MRNA

NVAX

FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.

JPMorganChase Today Launched The JPMorganChase Center For Geopolitics, A Client Advisory Service That Will Harness The Company's Unparalleled Network, Expertise, And Resources To Help Clients Successfully Navigate The Increasingly Complex Global Business Landscape

Needham analyst Tom Nikic maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and lowers the price target from $246 to $150.

DECK

Needham Maintains Buy on Deckers Outdoor, Lowers Price Target to $150

SPNS

Sapiens International Announced Today That A Leading State-run Auto Insurance Placement And Claims Organization Has Selected Sapiens ClaimsPro For Property & Casualty (P&C) To Support Its Modernization Efforts

In addition to establishing the Enterprise Acceleration Office, the company shared a number of changes across its executive leadership team to more closely align key capabilities that will support further speed and connection across the organization.&nbsp;
<ul>
<li>Prat Vemana, chief information and product officer, will report directly to Brian Cornell and take on leadership of the Target in India global capability center.</li>
<li>Jim Lee, chief financial officer, will take on leadership of Target's enterprise strategy and partnerships.</li>
<li>Rick Gomez, chief commercial officer, will oversee Target's enterprise insights team.</li>
<li>With these changes, Christina Hennington, chief strategy and growth officer, will depart Target and move into a strategic advisor role through Sept. 7, 2025.</li>
</ul>

Management

Target: CFO Jim Lee Will Take On Leadership Of Company's Enterprise Strategy And Partnerships

<ul>
<li>The Company has established an acceleration office led by Michael Fiddelke, with the purpose of enabling faster decisions and execution of its core strategic initiatives in support of a return to growth.</li>
</ul>

Target Has Established An Acceleration Office Led By Michael Fiddelke For Enabling Faster Decisions And Execution Of Core Strategic Initiatives

Guidance
For fiscal 2025, the Company now expects a low-single digit decline in sales, and GAAP EPS of $8.00 to $10.00.&nbsp; Adjusted EPS, which excludes the gains from the litigation settlements in the first quarter, is expected to be approximately $7.00 to $9.00.

Target Widens FY2025 GAAP EPS Guidance from $8.80-$9.80 to $8.00-$10.00 vs $8.54 Est

Press Releases

KindlyMD(TM) Recognized with Healthcare AI Impact Award 2024

Events

KindlyMD(TM) to Participate in Upcoming October Conferences

KindlyMD(TM) Announces Contract with United Healthcare Insurance, the Largest Health Insurer in the United States

KindlyMD(TM) Announces $500,000 Share Repurchase Program

Contracts

KindlyMD(R) Announces New Partnership With Cigna Healthcare to Further Expand Patient Care Accessibility

KindlyMD(R) Announces Third Quarter 2024 Financial Results

KindlyMD(R) Opens New Integrated Behavioral Health Clinic on the Ogden Regional Medical Center Campus

David Bailey and Bitcoin-Native Holding Company Nakamoto Announce Merger with KindlyMD® to Establish Bitcoin Treasury

Stocks Under $5 to Watch: KDLY, PRSO, NXTT, GRYP, YHC Lead Headlines with Bitcoin, AI, and Semiconductor Catalysts

KindlyMD® Shareholders Approve Proposed Merger with Nakamoto Holdings

GRYP

KDLY

NXTT

PRSO

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Kindly MD

Kindly MD (KDLY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO